The specific embodiment
Come further to set forth medicine of the present invention and preparation method thereof by the following examples, these embodiment have comprised toxicity test, pharmacodynamics test and the clinical efficacy result of the test of medicine of the present invention.But this should be interpreted as that scope of the present invention only limits to following embodiment, every technology that realizes based on foregoing of the present invention all belongs to the scope of protection of present invention.
Embodiment 1: the preparation of medicine capsule of the present invention
Get Radix Et Rhizoma Rhei 250g, Eupolyphaga Seu Steleophaga 200g, Hirudo 205g, Semen Persicae 175g, Pollen Typhae 160g, Radix Scutellariae 122g, Fructus Aurantii Immaturus 175g, Concha Ostreae 240g, Radix Rehmanniae 230g, Radix Paeoniae Alba 186g, Radix Glycyrrhizae 60g, wherein eight flavor medicines such as Radix Et Rhizoma Rhei, Eupolyphaga Seu Steleophaga, Hirudo, Pollen Typhae, Fructus Aurantii Immaturus, Radix Rehmanniae, the Radix Paeoniae Alba, Radix Glycyrrhizae add 10 times of water gagings immersions 2 hours, add Semen Persicae, the Radix Astragali two flavor medicines decoctions 1.5 hours after boiling, medicinal residues add 8 times of water gagings again and decocted 1 hour, and decocting liquid filters the back and merges, and is evaporated to relative density and is about 1.20 (65 ℃); Concha Ostreae decocts with method and concentrates, merge with aforementioned concentrated solution, vacuum drying, pulverize extract powder.Get 1 part of extract powder, 0.25 part of starch is used an amount of alcohol granulation, drying, and 20 mesh sieve granulate, encapsulated, make 1000, promptly.This product 3 times on the one is taken 3 at every turn.
Embodiment 2: the preparation of medicinal tablet of the present invention
Get Radix Et Rhizoma Rhei 125g, Eupolyphaga Seu Steleophaga 100g, Hirudo 105g, Semen Persicae 90g, Pollen Typhae 82g, Radix Scutellariae 60g, Fructus Aurantii Immaturus 86g, Concha Ostreae 120g, Radix Rehmanniae 115g, Radix Paeoniae Alba 94g, Radix Glycyrrhizae 31g, wherein eight flavor medicines such as Radix Et Rhizoma Rhei, Eupolyphaga Seu Steleophaga, Hirudo, Pollen Typhae, Fructus Aurantii Immaturus, Radix Rehmanniae, the Radix Paeoniae Alba, Radix Glycyrrhizae add 10 times of water gagings immersions 2 hours, add Semen Persicae, the Radix Astragali two flavor medicines decoctions 1 hour after boiling, medicinal residues add 8 times of water gagings again and decocted 1 hour, and decocting liquid filters the back and merges, and is evaporated to relative density and is about 1.20 (65 ℃); Concha Ostreae decocts and concentrates with method, merges with aforementioned concentrated solution, makes bed material with the starch of extractum amount about 35%, and spray adds extractum and carries out one-step palletizing, and granulate is pressed into 1000, coating, promptly.This product 3 times on the one is taken 6 at every turn.
Embodiment 3: the preparation of drug mixture of the present invention
Get Radix Et Rhizoma Rhei 70g, Eupolyphaga Seu Steleophaga 65g, Hirudo 55g, Semen Persicae 50g, Pollen Typhae 48g, Radix Scutellariae 36g, Fructus Aurantii Immaturus 50g, Concha Ostreae 72g, Radix Rehmanniae 75g, Radix Paeoniae Alba 48g, Radix Glycyrrhizae 18g, wherein Radix Et Rhizoma Rhei, Eupolyphaga Seu Steleophaga, Hirudo, Pollen Typhae, Fructus Aurantii Immaturus, Radix Rehmanniae, the Radix Paeoniae Alba, eight flavor medicines such as Radix Glycyrrhizae add 11 times of water gagings and soaked 3 hours, add Semen Persicae after boiling, the Radix Astragali two flavor medicines decocted 2 hours, and medicinal residues add 9 times of water gagings again and decocted 1.5 hours, and decocting liquid filters the back and merges, be evaporated to relative density 1.15~1.20 (60 ℃), add ethanol and make and contain alcohol amount and reach 65%~70%, leave standstill after 24 hours and filter, decompression filtrate recycling ethanol, centrifugal, get supernatant, add cyclamate 0.4g, sorbic acid 2g, polyoxyethylene sorbitan monoleate 9g, mixing adds water to 1000ml, filter, fill, sterilization, promptly.This product 3 times on the one is taken 10ml at every turn.
Embodiment 4: the preparation of medicinal granule of the present invention
Get Radix Et Rhizoma Rhei 240g, Eupolyphaga Seu Steleophaga 200g, Hirudo 200g, Semen Persicae 180g, Pollen Typhae 160g, Radix Scutellariae 120g, Fructus Aurantii Immaturus 180g, Concha Ostreae 240g, Radix Rehmanniae 240g, Radix Paeoniae Alba 180g, Radix Glycyrrhizae 60g, wherein eight flavor medicines such as Radix Et Rhizoma Rhei, Eupolyphaga Seu Steleophaga, Hirudo, Pollen Typhae, Fructus Aurantii Immaturus, Radix Rehmanniae, the Radix Paeoniae Alba, Radix Glycyrrhizae add 9 times of water gagings immersions 1 hour, add Semen Persicae, the Radix Astragali two flavor medicines decoctions 1.5 hours after boiling, medicinal residues add 8 times of water gagings again and decocted 1 hour, and medicinal residues add 7 times of water gagings again and decocted 0.5 hour, decocting liquid filters the back and merges, and is evaporated to relative density and is about 1.10 (65 ℃); Concha Ostreae decocts and concentrates with method, merges with preceding concentrated solution, and spray drying adds 2g sugar of sweet generation and appropriate amount of starch, granulates, and drying is made 1000g, is packed as every bag of 3g, promptly.This product 3 times on the one is taken 1 bag at every turn.
Toxicity test:
Get 20 of Kunming mouses, male and female half and half, body weight 18~20g, fasting after 12 hours Cmax and the heap(ed) capacity with drug suspension of the present invention irritate stomach at twice, one day dosage be equivalent to 600 times of a clinical consumption per day, rat feed in one week as a result, drinking-water and behavioral activity are normal, smooth by hair, eye, ear, mouth, the no abnormal secretions in nose place, feces is normal, none is only dead, weight gain value is 4.6 ± 1.3 (g of X ± SD).
Get 80 of rats, in one week of breeding observing, be divided into 3 groups by sex, body weight stratified random, matched group and each 30 of heavy dose of groups, 20 of small dose group.Large and small dosage group gavages 120 times and 60 times the medicine of the present invention that is equivalent to a clinical consumption per day respectively, matched group gavages the isometric(al) normal saline, once a day, successive administration 180 days (per 15 days according to body weight change adjustment dosage once) continues after the drug withdrawal to observe 15 days.Medicine of the present invention as a result is to the animal appearance sign, behavioral activity, body weight gain, erythrocyte (R.B.C), leukocyte (W.B.C) sum and classification, hematological indices such as platelet (P.C) counting and hemoglobin (Hb) content, glutamate pyruvate transaminase (GPT), alkali phosphatase (ALP), total protein (TP), albumin (ALB), blood urea nitrogen (BuN), creatinine blood biochemicals such as (Cr) is learned index, the heart, liver, spleen, lung, kidney, testis, the uterus, main organs coefficients such as ovary all do not have obvious influence, obvious pathological lesion is not seen in the main organs histological examination, 15 days hematological indices of drug withdrawal, blood biochemical is learned index, main organs coefficient etc. is not also found retardance toxic reaction (the every index and the matched group of above each administration group relatively are P>0.05).
Pharmacodynamics test:
One, the estrogenic antagonist of medicine of the present invention
(1) to the influence of mouse uterine weight
Get 72 of mices, be divided into 6 groups at random: (1) normal control group, (2) diethylstilbestrol group (model contrast) by body weight; (3)~(5) the large, medium and small dosage group of diethylstilbestrol+medicine of the present invention, (6) diethylstilbestrol+methyl testosterone group (positive control).Except that the normal control group, each group gavages diethylstilbestrol earlier by the listed dosage of table 1, (3)~(6) 2h irritated the corresponding medicine of stomach again after group gavaged diethylstilbestrol, irritate the stomach volume and be 0.2ml/10g, normal control group and model control group gavage isometric(al) 1%CMC solution, be administered once every day, successive administration 5 days.24h after the last administration, mice takes off the uterus by only weighing and taking off cervical vertebra and put to death, peel off the tissue that adheres to, inhale with filter paper and go tissue fluid, put on the electronic balance (sensibility reciprocal 0.1mg) and weigh, calculate its uterus coefficient, organize a significant difference relatively (as follows), the results are shown in Table 1 with the t check.
The influence of table 1 pair mouse uterine weight
Group | Dosage (g/kg * 5d) | Number of animals (only) | The uterus coefficient (the mg/10g body weight, X ± SD) |
Normal control | ??- | ??12 | ??10.2±4.1 |
Diethylstilbestrol | ??2×10
-4 | ??12 | ??44.1±5.4
△△△ |
Diethylstilbestrol+medicine of the present invention | ??2×10
-4,10
| ??12 | ??39.3±5.8
*△△△ |
Diethylstilbestrol+medicine of the present invention | ??2×10
-4,5
| ??12 | ??39.1±4.0
*△△△ |
Diethylstilbestrol+medicine of the present invention | ??2×10
-4,2
| ??12 | ??41.3±7.2
△△△ |
Diethylstilbestrol+methyl testosterone | ??2×10
-4,1.2×10
-2 | ??12 | ??35.3±3.7
***△△△ |
Compare with the diethylstilbestrol group:
*P<0.05,
* *P<0.001
Compare with the normal control group:
△ △ △P<0.001
Table 1 is the result show, diethylstilbestrol can promote the uterine growth of mice childhood, and the uterus coefficient enlarges markedly, and the mouse uterine weight that gives medicine 10 of the present invention, 5g/kg simultaneously alleviates, the uterus coefficient is significantly less than the diethylstilbestrol group, points out medicine of the present invention to have antiestrogenic effect.
(2) serum estradiol assay
Get 56 of rats, be divided into 7 groups at random by body weight, according to listed dosage of table 2 and administration, to irritate the stomach volume and be 1.5ml/100g, normal control group and estradiol benzoate group gavage isometric(al) 1%CMC solution, once a day, successive administration 10 days, 24h after the last administration, vascular plexus is got blood behind the socket of the eye, get serum and respectively organize the rat blood serum estradiol content, the results are shown in Table 2 with radio immunoassay mensuration.
The influence of table 2 pair rat blood serum estradiol level
Group | Dosage (g/kg * 10d) | Route of administration | Number of animals (only) | Serum estradiol (pg/ml, X ± SD) |
Normal control | ??- | ??ig | ??8 | ??26.2±11.9 |
Medicine of the present invention | ??10 | ??ig | ??8 | ??18.5±8.7 |
Medicine of the present invention |
??2 |
??ig |
??8 |
??23.9±10.7 |
Methyl testosterone |
??1.2×10
-2 |
??ig |
??8 |
??15.1±7.1
△ |
Estradiol benzoate |
??2.5×10
-4 |
??iM |
??8 |
??227.9±62.4
△△△ |
Estradiol benzoate+medicine of the present invention |
??2.5×10
-4,10
|
??iM,ig |
??8 |
??124.4±50.9
△△** |
Estradiol benzoate+medicine of the present invention |
??2.5×10
-4,2
|
??iM,ig |
??8 |
??178.0±78.3
△△△ |
Compare with the normal control group: △ P<0.05, △ △ P<0.01, △ △ △ P<0.001.
Compare with the estradiol benzoate group:
*P<0.01.
By table 2 as seen, the large and small dosage group of medicine of the present invention serum estradiol content and normal control group compare, though reduction is in various degree arranged, there are no significant for difference (P>0.05), shows that medicine does not make significant difference to the normal rat estradiol level; Behind the rat intramuscular injection estradiol benzoate, the serum estradiol level significantly raises, and gives 10 simultaneously, the medicine of the present invention of 2g/kg, can reduce the content of estradiol in the serum, with acting as significantly of heavy dose.Point out medicine of the present invention that the effect of the exogenous estrogen rising serum estradiol of antagonism is arranged.
Two, the function of promoting blood circulation to disperse blood clots of medicine of the present invention
(1) to the effect of " blood circulating out of vessels " type syndrome of blood stasis mice
Get 48 of mices, by body weight be divided in matched group, the medicine of the present invention at random, small dose group and FUFANG DANSHEN PIAN group (positive control), according to the listed dosage gastric infusion of table 2, the administration volume is 0.2ml/10g, matched group gavages isometric(al) 1%CMC solution, once a day, and successive administration 3 days.1h after the last administration, in every mouse peritoneal, inject 10% hematocrit sheep red blood cell (SRBC) (SRBC) suspension 0.3ml (about 600,000,000 SRBC), take off cervical vertebra behind the 4h and put to death mice, abdominal part cuts open an osculum, draw peritoneal fluid 20 μ l in the 4ml erythrocyte diluting fluid with hemoglobin straw, mixing is put residual SRBC number in the microscopically counting peritoneal fluid, the results are shown in Table 3.
Table 3 is to the influence of residual SRBC number in " blood circulating out of vessels " type syndrome of blood stasis mouse peritoneal liquid
Group | Dosage (g/kg * 3d) | Number of animals (only) | SRBC number (* 10
12/L, X±SD)
|
Contrast | ??- | ??12 | ??1.16±0.31 |
Medicine of the present invention | ??5 | ??12 | ??0.88±0.27
* |
Medicine of the present invention |
??2 |
??12 |
??0.98±0.29 |
FUFANG DANSHEN PIAN |
??0.08 |
??12 |
??0.81±0.24
** |
Annotate: FUFANG DANSHEN PIAN 0.08g/kg is 13.9 times of a clinical consumption per day.
Compare with matched group:
*P<0.05,
*P<0.01
Table 3 is the result show, medicine 5g/kg of the present invention can make that residual SRBC number obviously reduces in the mouse peritoneal liquid, with identical clinical consumption multiple relatively, its effect and FUFANG DANSHEN PIAN there was no significant difference, prompting 5g/kg medicine of the present invention has the effect that promotes that the intraperitoneal sheep red blood cell (SRBC) absorbs.
(2) to the microcirculatory influence of rabbit " blood stasis " model due to the macromolecule glucosan
Choose 40 of rabbit, make a labelling, select blood capillary clearly, measure its blood flow rate and blood flow, observe the blood fluidised form simultaneously in mark in every rabbit left side have sharp ears portion.Be divided into 5 groups of (normal control groups at random by survey blood flow rate value, model control group, in the medicine of the present invention, small dose group and FUFANG DANSHEN PIAN group), press the listed dosage gastric infusion of table 4, the administration volume is 13ml/kg, normal control group and model control group gavage 1%CMC solution, each is organized and is administered once every day, successive administration 5 days, 1h after the last administration, model group and each administration group rabbit right ear vein are injected 12% dextran solution 10ml/kg, the quiet notes isometric(al) of normal control group normal saline, measure microvascular blood flow rate in same position and blood flow with method behind the 20min, observe the blood fluidised form, the results are shown in Table 4.
The influence of " blood stasis " model rabbit have sharp ears portion's microvascular blood flow velocity and blood flow due to the table 4 pair glucosan (X ± SD)
Group | Dosage (g/kg * 5d) | Number of animals (only) | Blood flow rate (mM/S) | Blood flow (* 10
3μM
3/s)
|
Normally | After moulding and the administration | Normally | After moulding and the administration |
Normal control | ??- | ??8 | ??0.318±0.049 | ??0.331±0.051 | ??15.6±6.5 | ??16.0±4.3 |
The model contrast | ??- | ??8 | ??0.328±0.048 | ??0.191±0.067
△△△ | ??16.4±4.4 | ??9.4±2.8
△△ |
Medicine of the present invention | ??6 | ??8 | ??0.319±0.054 | ??0.264±0.047
*△ | ??15.3±3.5 | ??13.1±2.9
* |
Medicine of the present invention | ??2 | ??8 | ??0.321±0.051 | ??0.239±0.054
△△ | ??15.6±4.3 | ??10.4±3.1
△△ |
FUFANG DANSHEN PIAN | ??0.1 | ??8 | ??0.323±0.055 | ??0.278±0.041
**△ | ??15.4±4.8 | ??14.0±4.4
* |
Compare with model control group:
*P<0.05,
*P<0.01
Compare with the normal control group:
△P<0.05,
△ △P<0.01,
△ △ △P<0.001
By table 4 as seen, after the moulding of rabbit vein injection macromolecule dextran solution, microvascular blood flow velocity obviously slows down, blood flow significantly reduces, observing the blood fluidised form simultaneously changes, become I level (dotted line shape) or II level (granular) by 0 grade (linearity), and, show that animal has been " blood stasis " state of microcirculation disturbance based on the II level.Medicine 6g/Kg treated animal of the present invention shows microvascular blood flow velocity and significantly speeds, and blood flow obviously increases, and the blood fluidised form also has improvement in various degree, and 2/3 animal transfers the I level to by the II level.The medicine of the present invention of prompting 6g/Kg has the microcirculatory effect of the blood stasis of improvement rabbit.
(3) to the influence of " blood stasis " type rabbit blood rheology index due to the glucosan
40 of rabbit, grouping, administration are all with experiment (two), 1h after the last administration, model group and each administration group man rabbit ear vein are injected 12% dextran solution 10ml/kg, and heart extracting blood is made whole blood and plasma viscosity mensuration behind the 1h, and measure plasma fibrinogen content, the results are shown in Table 5.
The influence of " blood stasis " type rabbit blood viscosity and plasma fibrinogen due to the table 5 pair glucosan (X ± SD)
Group | Dosage (g/kg * 5d) | Number of animals (only) | Whole blood viscosity (mpa.s) | Plasma viscosity | Plasma fibrinogen |
??230.0S
-1 | ??5.8s
-1 | ??(mpa.s) | ??(g/L) |
Normal control | | ??8 | ??2.21±0.31 | ??6.78±1.13 | ??1.38±0.20 | ??1.81±0.31 |
The model contrast | | ??8 | ??3.75±0.56
△△△ | ??10.61±1.45
△△△ | ??2.12±0.27
△△△ | ??2.56±0.83
△ |
Medicine of the present invention | ??6 | ??8 | ??3.13±0.49
*△△△ | ??9.05±1.31
*△△ | ??1.92±0.24
△△△ | ??2.01±0.40 |
Medicine of the present invention | ??2 | ??8 | ??3.49±0.52
△△△ | ??9.67±1.14
△△△ | ??2.08±0.36
△△△ | ??2.14±0.44 |
FUFANG DANSHEN PIAN | ??0.1 | ??8 | ??2.86±0.61
**△ | ??8.47±1.27
**△ | ??1.83±0.21
*△△△ | ??2.03±0.72 |
Compare with model control group:
*P<0.05,
*P<0.01
Compare with the normal control group:
△P<0.05,
△ △P<0.01,
△ △ △P<0.001
Table 5 is the result show, behind the rabbit injection macromolecule dextran solution, the obvious change of hemorheological properties occurs, shows as whole blood viscosity with plasma viscosity increases, and plasma fibrinogen content is significantly rising all.Whole blood viscosity, plasma viscosity and the fibrinogen content of two dosage groups of medicine of the present invention rabbit all has decline in various degree, with 6g/Kg being reduced to significantly whole blood viscosity (Gao Qie cuts with low).
Three, the antiinflammatory action of medicine of the present invention
(1) influence that the mouse skin capillary permeability is increased
Get 60 of mices, by sex, body weight is divided into 5 groups at random, gavage medicine of the present invention respectively according to the listed dosage of table 6, prednisolone acetate, the administration volume is 0.2ml/10g, matched group gavages isometric(al) 1%CMC solution, once a day, and successive administration 3 days, 1h after the last administration, every mouse tail vein injection 1% azovan blue solution 0.1ml/10g drips in skin of abdomen (losing hair or feathers) immediately and is coated with dimethylbenzene 10 μ l and causes inflammation, puts to death animal behind the 20min, cut the scorching position of caused by dimethylbenzene xylene indigo plant and dye skin, shred the back and immerse in the 2.5ml acetone normal saline, room temperature is placed 24h, gets supernatant after centrifugal to put 721 spectrophotometer 610nm colorimetrics, record O.D value the results are shown in Table 6.
The table 6 pair influence that the mouse skin capillary permeability increases
Group | Dosage (g/kg * 3d) | Number of animals (only) | Skin leachate O.D value (X ± SD) |
Contrast | | ??12 | ??0.107±0.038 |
Medicine of the present invention | ??10 | ??12 | ??0.069±0.032
* |
Medicine of the present invention | ??5 | ??12 | ??0.082±0.029 |
Medicine of the present invention | ??2 | ??12 | ??0.105±0.036 |
Prednisone | ??0.02 | ??12 | ??0.064±0.024
** |
Compare with matched group:
*P<0.05,
*P<0.01
Table 6 is the result show, medicine 10g/kg xylol induced mice capillary of skin permeability of the present invention increases remarkable inhibitory action, and 5g/kg only has inhibition trend.
(2) to the granulomatous influence of rat plastic hoop
40 of rats are divided into 5 groups by sex, body weight.Under surgical condition, in subcutaneous one of the plastic hoop that internal diameter is 5mm (known weight) of respectively imbedding of rat two forelimb armpits, the operation time listed dosage of table 6 at sunshine gavages medicine of the present invention and prednisolone acetate respectively, the administration volume is 1.5ml/100g, once a day, successive administration 10 days, 24h puts to death rat after the last administration, take out the plastic hoop that has been enclosed with granulation tissue, remove surface texture liquid with the filter paper suction, put on the electronic balance (sensibility reciprocal 0.1mg) and weigh, deduct former plastic hoop weight and be the granulation tissue weight in wet base, the results are shown in Table 7.
The table 7 pair granulomatous influence of rat plastic hoop
Group | Dosage (g/kg * 10d) | Plastics number of rings (individual) | The granuloma weight in wet base (mg, X ± SD) |
Contrast | ??- | ??16 | ??69.5±20.4 |
Medicine of the present invention | ??10 | ??16 | ??47.2±12.8
** |
Medicine of the present invention | ??5 | ??16 | ??55.3±17.0
* |
Medicine of the present invention | ??2 | ??16 | ??55.1±13.9
* |
Prednisone | ??0.02 | ??16 | ??40.7±15.0
*** |
Compare with matched group:
*P<0.05,
*P<0.01,
* *P<0.001.
Table 7 is the result show, medicine 10,5 of the present invention, 2g/kg all can significantly suppress the granulomatous formation of rat plastic hoop, and granulation tissue weight is obviously alleviated, and the inhibitory action of 10g/kg is the strongest.
Four, the anastalsis of medicine of the present invention
(1) mice bleeding time
60 of mices are divided into 5 groups at random by sex, body weight, gavage medicine of the present invention and carbazochrome salicylate respectively according to the listed dosage of table 8, and irritating the stomach volume is 0.2ml/10g, and matched group gavages isometric(al) 1%CMC, once a day, and successive administration 3 days.1h after the last administration, every mice is cut cross-section with profit apart from tail point 3mm place, timing, every interval 0.5min inhales docking place drop of blood once gently with filter paper, till blood stops (depletion of blood when filter paper is inhaled) naturally, in the calculating bleeding time, the results are shown in Table 8.
The influence in table 8 pair mice bleeding time
Group | Dosage (g/kg * 3d) | Number of animals (only) | Bleeding time (min, X ± SD) |
Contrast | ??- | ??12 | ??8.21±3.92 |
Medicine of the present invention | ??10 | ??12 | ??5.08±2.34
* |
Medicine of the present invention | ??5 | ??12 | ??5.13±2.12
* |
Medicine of the present invention | ??2 | ??12 | ??7.29±3.41 |
Carbazochrome salicylate | ??0.01 | ??12 | ??4.33±2.17
** |
Compare with matched group:
*P<0.05,
*P<0.01
By table 8 as seen, medicine 10 of the present invention, 5g/kg all can make the mice docking bleeding time significantly shorten, and 2g/kg then only has the trend that shortens the bleeding time.
(2) clotting time of mice is measured
60 of mices are divided into 5 groups at random by sex, body weight, according to the listed dosage gastric infusion of table 9, once a day, successive administration 3 days.1h after the last administration, with being about 8cm, the capillary glass tube of the about 1mm of internal diameter inserts mice endocanthion ball rear vein beard and gets blood, be full of to the capillary tube inner blood, every interval 0.5min a bit of capillary tube that fractures gently, scrutiny has or not the blood clotting silk to occur, and as clotting time, the results are shown in Table 9 from the capillary tube blood sampling to the time that the blood clotting silk occurs.
The influence of table 9 pair clotting time of mice
Group | Dosage (g/kg * 3d) | Number of animals (only) | Clotting time (min, X ± SD) |
Contrast | ??- | ??12 | ??3.45±0.67 |
Medicine of the present invention | ??10 | ??12 | ??2.38±0.88
** |
Medicine of the present invention | ??5 | ??12 | ??2.67±0.94
* |
Medicine of the present invention | ??2 | ??12 | ??3.00±1.02 |
Carbazochrome salicylate |
??0.01 |
??12 |
??2.25±0.66
*** |
Compare with matched group:
*P<0.05,
*P<0.01,
* *P<0.001
Table 9 is the result show, medicine 2g/Kg of the present invention slightly shortens clotting time of mice, compares there was no significant difference with matched group; But obviously shorten along with drug dose increases clotting time, the most remarkable with the 10g/Kg effect, three dosage groups present certain dose-effect relationship.
Five, the immunological enhancement of medicine of the present invention
(1) to the huge influence of biting function of mouse monokaryon
1, test for the first time
Adopt the carbon clearance method.Get 84 of Kunming mouses, be divided into 7 groups at random by sex, body weight, every group of male and female half and half, according to listed dosage of table 10 and administration, the gastric infusion volume is 0.2ml/10g, and the intraperitoneal injection volume is 0.1ml/10g, and normal control group and cyclophosphamide group gavage isometric(al) 1%CMC, once a day, give 7 days continuously.Next day after the drug withdrawal, every mouse tail vein injection india ink (chroma, West Germany produces) 0.1ml/10g, inject back 0.5 minute with 3 minutes respectively behind socket of the eye vascular plexus get blood 30 μ l, add among the 0.1% Carbon Dioxide sodium solution 2ml, shake up, put 721 spectrophotometers (675nm) and measure the OD value, be calculated as follows phagocytic index K.The results are shown in Table 10.
2, test for the second time
72 of Kunming mouses are divided into 6 groups at random, press dosage shown in the table 11 and approach successive administration 7 days, and all the other methods the results are shown in Table 11 with test for the first time.
Table 10 medicine of the present invention is to the influence of mouse monokaryon macrophage phagocytic function
Group | Dosage (g/kg * 7d) | Route of administration | Number of animals (only) | Phagocytic index K (X ± SD) |
Contrast | ??- | ??ig | ??12 | ??0.0450±0.0127 |
Medicine of the present invention | ??10 | ??ig | ??12 | ??0.0553±0.0171 |
Medicine of the present invention | ??5 | ??ig | ??12 | ??0.0478±0.0166 |
Medicine of the present invention | ??2 | ??ig | ??12 | ??0.0452±0.0107 |
Polyactin | ??0.012 | ??ig | ??12 | ??0.0602±0.0173
* |
Cyclophosphamide | ??0.02 | ??ip | ??12 | ??0.0317±0.0096
** |
Cyclophosphamide+medicine of the present invention |
??0.02,10 |
??ip,ig |
??12 |
??0.0412±0.0110
△ |
Compare with matched group:
*P<0.05,
*P<0.01
Compare with the cyclophosphamide group:
△P<0.05
Table 11 medicine of the present invention is to the influence of immunologic hypofunction mouse monokaryon macrophage phagocytic function
Group | Dosage (g/kg * 7d) | Route of administration | Number of animals (only) | Phagocytic index K (X ± SD) |
Normal control | ??- | ??ig | ??12 | ??0.0338±0.0116 |
Cyclophosphamide | ??0.02 | ??ip | ??12 | ??0.0208±0.0082
** |
Cyclophosphamide+medicine of the present invention | ??0.02,10 | ??ip,ig | ??12 | ??0.0291±0.0088
△ |
Cyclophosphamide+medicine of the present invention | ??0.02,5 | ??ip,ig | ??12 | ??0.0319±0.0113
△ |
Cyclophosphamide+medicine of the present invention | ??0.02,2 | ??ip,ig | ??12 | ??0.0271±0.0091 |
Cyclophosphamide+polyactin | ??0.02,0.018 | ??ip,ig | ??12 | ??0.0310±0.0083
△△ |
Compare with the normal control group:
*P<0.01
Compare with the cyclophosphamide group: △ P<0.05, △ △ P<0.01
Table 10 shows that with table 11 result medicine of the present invention does not have obvious influence to the phagocytic function of normal mouse monokaryon macrophage.Cyclophosphamide can suppress the phagocytic function of mouse monokaryon macrophage, phagocytic index is significantly reduced, give and 10g/kg, 5g/kg medicine of the present invention simultaneously, its phagocytic index obviously increases, and the medicine of the present invention of the big or middle dosage of prompting can strengthen the non-specific phagocytic function under the mouse immune inhibitory state.
(2) to the active influence of NK cells in mice
1, test for the first time
60 of NIH mices, be divided into 6 groups at random by sex, body weight, every group of male and female half and half, press dosage shown in the table 12 and administration, once a day, successive administration 7 days, 24h puts to death mice after the last administration, the sterile working wins spleen and makes splenocyte suspension, mixes the inhibition method with 3h-TUR and measures the NK cytoactive.The results are shown in Table 12.
2, test for the second time
60 of NIH mices are divided into 5 groups at random, press dosage shown in the table 13 and approach successive administration 7 days, and all the other methods the results are shown in Table 13 with test for the first time.
Table 12 medicine of the present invention is to the active influence of NK cells in mice
Group | Dosage (g/kg * 7d) | Route of administration | Number of animals (only) | The NK cytoactive (Pi, X ± SD) |
Contrast | ??- | ??ig | ??10 | ??39.8±4.8 |
Medicine of the present invention | ??10 | ??ig | ??10 | ??43.3±5.5 |
Medicine of the present invention | ??2 | ??ig | ??10 | ??41.7±4.4 |
Polyactin | ??0.012 | ??ig | ??10 | ??45.6±2.4
** |
Cyclophosphamide | ??0.02 | ??ip | ??10 | ??27.6±4.5
*** |
Cyclophosphamide+medicine of the present invention | ??0.02,10 | ??ip,ig | ??10 | ??31.7±3.7
***△
|
Compare with matched group:
*P<0.01,
* *P<0.001
Compare with the cyclophosphamide group: △ P<0.05
Table 13 medicine of the present invention is to the active influence of immunologic hypofunction NK cells in mice
Group | Dosage (g/kg * 7d) | Route of administration | Number of animals (only) | The NK cytoactive (%, X ± SD) |
Normal control |
??- |
??ig |
??12 |
??41.5±4.5 |
Cyclophosphamide |
??0.02 |
??ip |
??12 |
??28.5±4.6
*** |
Cyclophosphamide+medicine of the present invention |
??0.02,10 |
??ip,ig |
??12 |
??33.4±5.6
△ |
Cyclophosphamide+medicine of the present invention |
??0.02,2 |
??ip,ig |
??12 |
??31.2±4.6
△ |
Cyclophosphamide+polyactin |
??0.02,0.018 |
??ip,ig |
??12 |
??46.9±4.4
△△△ |
Compare with the normal control group:
* *P<0.001
Compare with the cyclophosphamide group: △ P<0.05, △ △ △ P<0.001
By table 12, table 13 as seen, the large and small dosage group of medicine of the present invention NK cell killing activity and matched group relatively, there was no significant difference (P>0.05), the prompting medicine does not have an obviously influence to normal NK cells in mice is active.But the medicine of the present invention of heavy dose of (10g/kg) and low dose of (2g/kg) all can obviously resist cyclophosphamide to the active inhibitory action of NK cells in mice, improves the function of NK cell.
(3) to the influence of dinitrochlorobenzene (DNCB) inducing mouse delayed skin hypersensitivity
1, test for the first time
84 of Kunming mouses, by sex, body weight is divided into 7 groups at random, every group female, male half and half, 50% dinitrochlorobenzene (DNCB) acetone soln, 2 μ l sensitization are dripped in every mice back of the body skin of neck depilation district, sensitization rose according to dosage and administration shown in the table 14 same day, once a day, successive administration 10 days, 24h after the last administration, only carrying out skin of abdomen (losing hair or feathers) with 2.5%DNCB acetone soln 20 μ l/ attacks, the blue solution 0.1ml/10g of tail vein injection 1% ivens next day puts to death mice behind the 30min, strip the abdominal part orchid and dye skin, shred to soak in the rearmounted 2.5ml acetone normal saline solution and extract 24h, centrifugal, draw supernatant and put 721 spectrophotometers (610nm) mensuration OD value, the results are shown in Table 14.
2, test for the second time
72 of Kunming mouses are divided into 6 groups at random, in sensitization same day by dosage shown in the table 15 and administration 10 days, all the other methods the results are shown in Table 15 with test for the first time.
Table 14 medicine of the present invention is to the influence of DNCB induced mice DCHR
Group | Dosage (g/kg * 10d) | Route of administration | Number of animals (only) | Skin leachate O.D value (X ± SD) |
Contrast | ??- | ??ig | ??12 | ??0.088±0.030 |
Medicine of the present invention | ??10 | ??ig | ??12 | ??0.122±0.035
* |
Medicine of the present invention | ??5 | ??ig | ??12 | ??0.096±0.034 |
Medicine of the present invention | ??2 | ??ig | ??12 | ??0.087±0.026 |
Polyactin | ??0.012 | ??ig | ??12 | ??0.133±0.042
** |
Cyclophosphamide | ??0.02 | ??ip | ??12 | ??0.054±0.023
** |
Cyclophosphamide+medicine of the present invention | ??0.02,10 | ??ip,ig | ??12 | ??0.079±0.028
△ |
Compare with matched group:
*P<0.05,
*P<0.01.
Compare with the cyclophosphamide group:
△P<0.05.
Table 15 medicine of the present invention is to the influence of immunologic hypofunction mice delayed skin hypersensitivity
Group | Dosage (g/kg * 7d) | Route of administration | Number of animals (only) | Orchid is dyed skin leachate OD value (X ± SD) |
Normal control | ??- | ??ig | ??12 | ??0.102±0.029 |
Cyclophosphamide | ??0.02 | ??ip | ??12 | ??0.067±0.027
** |
Cyclophosphamide+medicine of the present invention | ??0.02,10 | ??ip,ig | ??12 | ??0.090±0.023
△ |
Cyclophosphamide+medicine of the present invention | ??0.02,5 | ??ip,ig | ??12 | ??0.092±0.025
△ |
Cyclophosphamide+medicine of the present invention |
??0.02,2 |
??ip,ig |
??12 |
??0.081±0.027 |
Cyclophosphamide+polyactin |
??0.02,0.018 |
??ip,ig |
??12 |
??0.096±0.031
△ |
Compare with the normal control group:
*P<0.01
Compare with the cyclophosphamide group: △ P<0.05
Show that by table 14, table 15 for the delayed skin hypersensitivity of normal mouse due to the DNCB, 10g/kg medicine of the present invention has remarkable potentiation; For the immune mice that is inhibitory state under the cyclophosphamide effect, 10g/kg and 5g/kg medicine of the present invention all can strengthen its delayed skin hypersensitivity.Point out medicine heavy dose of the present invention can improve the normal and low cellular immune function of mice, middle dosage can improve low cellular immune function.
(4) influence that sheep red blood cell (SRBC) sensitized mice hemolytic antibody is generated
1, test for the first time
84 of Kunming mouses, be divided into 7 groups at random, every group female, male half and half, dosage and administration (cyclophosphamide was only respectively injected once the previous day on the immunity same day and execution) according to table 16, once a day, successive administration 7 days, in administration after 4 days every mouse peritoneal inject 37% hematocrit sheep red blood cell (SRBC) (SRBC) suspension 0.2ml immunity, vascular plexus is got blood, separation of serum behind the 4th day eye socket in immunity back, by dilution in 1: 500, get this serum 1ml, add 5%SRBC suspension 0.5ml, put the guinea pig serum 1ml that adds dilution in 1: 10 in the ice bath, put into 37 ℃ of water-baths and react 10min, move to cessation reaction in the ice bath, centrifugal, get supernatant 1ml, add Dou Shi liquid 3ml, shake up, place behind the 10min with HD50 pipe (5% SRBC suspension 0.25ml adds Dou Shi liquid 3.75ml) simultaneously in 721 spectrophotometer 540nm colorimetrics, record O.D value is calculated as follows sample HC
50The results are shown in Table 16.
2, test for the second time
Get 72 of Kunming mouses, be divided into 6 groups at random, pressed the dosage of table 17 and approach successive administration 7 days, all the other methods the results are shown in Table 17 with test for the first time.
The influence that table 16 medicine of the present invention generates the mice hemolytic antibody
Group | Dosage (g/kg * 7d) | Route of administration | Number of animals (only) | ??HC
50??( X±SD)
|
Contrast | ??- | ??ig | ??12 | ??209.7±56.3 |
Medicine of the present invention | ??10 | ??ig | ??12 | ??248.1±46.0 |
Medicine of the present invention | ??5 | ??ig | ??12 | ??256.1±63.8 |
Medicine of the present invention | ??2 | ??ig | ??12 | ??190.0±60.6 |
Polyactin | ??0.012 | ??ig | ??12 | ??268.6±56.6
* |
Cyclophosphamide | ??0.02 | ??sc | ??12 | ??113.3±51.8
*** |
Cyclophosphamide+medicine of the present invention | ??0.02,10 | ??sc,ig | ??12 | ??153.3±57.9
* |
Compare with matched group:
*P<0.05,
* *P<0.001
The influence that table 17 medicine of the present invention generates immunologic hypofunction mice hemolytic antibody
Group | Dosage (g/kg * 7d) | Route of administration | Number of animals (only) | ??HC
50??( X±SD)
|
Normal control | ??- | ??ig | ??12 | ??191.6±42.4 |
Cyclophosphamide | ??0.02 | ??sc | ??12 | ??127.1±38.7
*** |
Cyclophosphamide+medicine of the present invention | ??0.02,10 | ??sc,ig | ??12 | ??165.5±36.0
△ |
Cyclophosphamide+medicine of the present invention | ??0.02,5 | ??sc,ig | ??12 | ??144.9±45.4
* |
Cyclophosphamide+medicine of the present invention |
??0.02,2 |
??sc,ig |
??12 |
??139.6±40.2
** |
Cyclophosphamide+polyactin |
??0.02,0.018 |
??sc,ig |
??12 |
??181.4±41.2
△△ |
Compare with the normal control group:
*P<0.05,
*P<0.01,
* *P<0.001
Compare with the cyclophosphamide group: △ P<0.05, △ △ P<0.01
By table 16,17 as seen, and medicine of the present invention has the trend that promotes that hemolytic antibody generates in the normal mouse body, the HC of big or middle dosage group
50Value all has certain program to improve than matched group, but there was no significant difference; For the mice that immunologic function is suppressed by cyclophosphamide, medicine heavy dose of the present invention can promote the formation of its hemolytic antibody, its HC
50Value is significantly improved than the cyclophosphamide group.
The clinical efficacy result of the test.
One, clinical efficacy test method:
The patients with uterine myoma that selection is made a definite diagnosis through auxiliary examinations such as gynecologial examination and B ultrasonic is treated.The Chinese medical discrimination standard is a syndrome of blood stasis: abdominal mass, and to fix and do not move, lower abdomen is made the dull pain that expands, menorrhagia or menostaxis, red menses or the purple dim piece that has, body of the tongue is dim red, and there is the ecchymosis point on the limit, deep and stringy pulse or carefully puckery.
The contrast therapeutic test stage is adopted the randomized controlled test, each 30 example of treatment group and matched group case, 1: 1 random packet.Enlarge the employing of contrast therapeutic test stage and contrast principle at random, 3: 1 random packet are pressed the random table numbering and are distributed treatment group and matched group, carry out in three tame hospitals respectively, and every family hospitalize group case is 90 examples, and the matched group case is 30 examples.Treat preceding two groups of patient's age, the course of disease distributes and average course of disease, menstrual cycle, menstrual period and menstrual blood volume, the hysteromyoma size, the uterus thickness and the uterine cavity degree of depth, tcm symptom, erythrocyte sum and hematochrome, hemorheology index, blood hormone-content there are no significant difference (P>0.05).
Each 3 of the capsule of oral medicine of the present invention is organized in treatment, every day three times (with contrast medicine GUIZHI FULING JIAONANG outward appearance, mouthfeel similar).The oral GUIZHI FULING JIAONANG of matched group, each 3, every day three times (with medicament appearance of the present invention, mouthfeel similar).Each 3, every day three times.Be three months two groups of courses of treatment.
Tcm symptom with in the mild symptoms weight classification table (+, ++, +++) expression after fill in.Mild symptoms multiple integral table sees Table 18.
Table 18 mild symptoms multiple integral table
Symptom | Gently (+) | In (++) | Heavy (+++) |
Lower abdomen expands | Idol has | Reach every day more than 6 hours | Abdominal distention all day |
Lower abdomen dull pain | Idol has | Take place frequently | Take place frequently, influence work |
Menorrhagia (total amount in menstrual period) |
100~120ml |
120~150ml |
>150ml |
Menostaxis |
8~10 days menstrual period |
11~12 days |
13~15 days |
The mild symptoms multiple integral by mild symptoms multiple integral table heavy+, ++, +++1 minute respectively, 2 minutes, 3 minutes. |
Curative effect determinate standard is:
(1) recovery from illness: muscular tumor disappears, clinical symptom disappearance.
(2) produce effects: muscular tumor is dwindled more than 1/2, and the mild symptoms multiple integral descends 〉=2/3 before the treatment.
(3) effective: muscular tumor dwindles 1/3, and the mild symptoms multiple integral reduces 〉=1/3~2/3 before the treatment.
(4) invalid: muscular tumor does not see obviously and dwindles that the mild symptoms multiple integral reduces less than 1/3 before the treatment.
Two, therapeutic outcome:
See Table 19~25.
Table 19 liang group patient total effects relatively
Group | The example number | Curative effect | Obvious effective rate % | Effective percentage % |
Recovery from illness | Produce effects | Effectively | Invalid |
The treatment group | ??300 | ??21 | ??122 | ??117 | ??40 | ??47.67 | ??86.67 |
Matched group | ??120 | ??4 | ??23 | ??42 | ??51 | ??22.50 | ??57.50 |
Two groups of curative effects are analyzed through RIDIT, and R controls=0.4470, and R is right=and 0.6324, u=5.95, P<0.01, difference has utmost point significance, illustrates that treatment group curative effect is better than matched group.
The curative effect of table 20 randomized controlled test relatively
Group | The example number | Curative effect | Obvious effective rate % | Effective percentage % |
Recovery from illness | Produce effects | Effectively | Invalid |
The treatment group | ??30 | ??3 | ??11 | ??11 | ??5 | ??46.67 | ??83.33 |
Matched group | ??30 | ??0 | ??7 | ??12 | ??11 | ??23.33 | ??63.33 |
Two groups of curative effects are analyzed through RIDIT, and R controls=0.4189, and R is right=and 0.5811, u=2.18, P<0.05, difference has significance, illustrates that treatment group curative effect is better than matched group.
The tcm symptom curative effect relatively behind the table 21 liang group patient treatment
Tcm symptom | Treatment group (300 example) | Matched group (120 example) | ??X2 | ??P |
Treatment precedent number | Produce effects example number | Obvious effective rate % | Treatment precedent number | Produce effects example number | Obvious effective rate % |
Menostaxis | ??214 | ??182 | ??85.05 | ??78 | ??50 | ??64.10 | ??14.10 | ??<0.01 |
Menorrhagia | ??260 | ??171 | ??65.77 | ??101 | ??22 | ??21.78 | ??54.82 | ??<0.01 |
Lower abdomen expands | ??232 | ??163 | ??70.26 | ??99 | ??60 | ??60.61 | ??2.52 | ??>0.05 |
Lower abdomen dull pain | ??229 | ??168 | ??73.36 | ??96 | ??53 | ??55.21 | ??9.43 | ??<0.01 |
Body of the tongue is unusual | ??216 | ??132 | ??61.11 | ??91 | ??42 | ??46.15 | ??5.24 | ??<0.05 |
The average of symptom integral and difference |
??4.59±2.38 |
??3.35±2.39 |
??t=4.82???P<0.01 |
Annotate: the symptom produce effects refers to treat the back symptom and reduces more than 2 grades or transference cure
Hysteromyoma size layering curative effect relatively behind the table 22 liang group patient treatment
Muscular tumor size (cm
3)
| Treatment group (300 example) | Matched group (120 example) |
The example number | Recovery from illness | Produce effects | Effectively | Invalid | Obvious effective rate % | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Obvious effective rate % |
??<5 | ??86 | ??13 | ??44 | ??23 | ??6 | ??66.28 | ??31 | ??1 | ??10 | ??9 | ??11 | ??35.48 |
??5~10 | ??80 | ??5 | ??30 | ??34 | ??11 | ??43.75 | ??32 | ??0 | ??5 | ??16 | ??11 | ??15.63 |
??>10 | ??134 | ??3 | ??48 | ??60 | ??23 | ??38.06 | ??57 | ??3 | ??8 | ??17 | ??29 | ??19.30 |
Two groups of hysteromyoma size layering (<5cm
3) curative effect relatively, analyze through RIDIT, R controls=0.4450, R is right=0.6525, u=3.43, P<0.01; Two groups of hysteromyoma size layering (5~10cm
3) curative effect relatively, analyze through RIDIT, R controls=0.4474, R is right=0.6316, u=3.05, P<0.01; Two groups of hysteromyoma size layering (>10cm
3) curative effect relatively, analyze through RIDIT, R controls=0.4480, R is right=0.6223, u=3.82, P<0.01; Above statistical analysis illustrates that all treatment group curative effect obviously is better than matched group.
The hysteromyoma size relatively behind the table 23 liang group patient treatment
Group | The example number | Muscular tumor size (cm
3)
|
Before the treatment | After the treatment | Difference |
The treatment group | ??300 | ??18.30±19.25 | ??10.07±13.77 | ??8.22±11.34??t=12.56??P<0.01 |
The T=t matched group | ??120 | ??19.00±21.06 | ??16.30±21.81 | ??2.65±10.99??t=2.64???P<0.01 |
Hysteromyoma dwindles difference relatively behind two groups of patient treatments, t=4.75, and P<0.01 illustrates that the treatment group dwindles the curative effect of hysteromyoma and obviously be better than matched group.
The thick footpath, uterus and the uterine cavity degree of depth behind the table 24 liang group patient treatment (X ± SD) relatively
Group | Thick footpath, uterus (cm) | The uterine cavity degree of depth (cm) |
Unusual routine number | Before the treatment | After the treatment | Difference | Unusual routine number | Before the treatment | After the treatment | Difference |
The treatment group | ??195 | ??5.66± ??????1.02 | ??5.25± ??????1.11 | ??0.41± ??????1.34 | ??164 | ??8.39± ??????0.72 | ??7.94± ??????0.75 | ??0.46± ??????0.41 |
Matched group | ??82 | ??5.83± ??????0.96 | ??5.64± ??????1.02 | ??0.20± ??????0.49 | ??56 | ??8.47± ??????0.70 | ??8.31± ??????0.75 | ??0.17± ??????0.27 |
The thick footpath, uterus and the uterine cavity degree of depth self compare before and after the treatment of treatment group, and the t value is respectively 4.27,3.70, and the P value all<0.01 illustrates that the treatment group has the definite effect of dwindling the thick footpath, uterus and the uterine cavity degree of depth; The minimizing difference of the treatment back uterine cavity degree of depth and matched group comparison, the t value is 4.94, P<0.05 illustrates that the treatment group dwindles the curative effect of the uterine cavity degree of depth and be better than matched group.
Hemorheology index curative effect behind the table 25 treatment group patient treatment
Hemorheology | Treatment group (23 example) | Matched group (14 example) |
Before the treatment | After the treatment | Difference | Before the treatment | After the treatment | Difference |
??J2 | ??3.71± ??????0.47 | ??3.61± ??????0.94 | ??0.20± ??????1.01 | ??3.57± ??????0.41 | ??3.79± ??????0.68 | ??0.22± ??????0.80 |
??J4 | ??6.58± ??????0.83 | ??6.38± ??????1.67 | ??0.20± ??????1.78 | ??6.32± ??????0.72 | ??6.71± ??????1.22 | ??0.39± ??????1.42 |
??J6 | ??11.61± ??????1.46 | ??11.26± ??????2.93 | ??0.35± ??????3.15 | ??11.15± ??????1.24 | ??11.84± ??????2.15 | ??0.69± ??????2.51 |
??J7 | ??1.40± ??????0.45 | ??1.13± ??????0.11 | ??0.27± ??????0.51 | ??1.27± ??????0.33 | ??1.15± ??????0.15 | ??0.21± ??????0.41 |
Height is cut reduced viscosity | ??7.66± ??????1.38 | ??6.77± ??????1.51 | ??0.89± ??????1.79 | ??7.29± ??????1.15 | ??6.90± ??????1.45 | ??0.39± ??????1.93 |
The low reduced viscosity of cutting | ??29.89± ??????4.70 | ??21.69± ??????4.36 | ??3.70± ??????4.70 | ??28.77± ??????3.82 | ??27.90± ??????3.41 | ??1.81± ??????3.14 |
??Ht | ??0.35± ??????0.05 | ??0.39± ??????0.05 | ??0.04± ??????0.07 | ??0.34± ??????0.03 | ??0.04± ??????0.04 | ??0.05± ??????0.05 |
Erythrocyte sedimentation rate | ??37.86± ??????17.89 | ??24.93± ??????14.08 | ??12.93± ??????12.68 | ??37.40± ??????6.75 | ??28.40± ??????10.27 | ??9.00± ??????11.70 |
Erythrocyte sedimentation rate K equation | ??95.78± ??????32.42 | ??69.86± ??????35.45 | ??25.92± ??????29.39 | ??95.27± ??????14.75 | ??91.5± ??????24.68 | ??3.77± ??????20.52 |
Fibrinogen | ??2.71± ??????0.56 | ??2.82± ??????0.59 | ??0.11± ??????0.52 | ??2.53± ??????0.23 | ??2.78± ??????0.36 | ??0.25± ??????0.36 |
Plasma viscosity, whole blood reduction ratio viscosity, erythrocyte sedimentation rate, erythrocyte sedimentation rate K equation all had obvious decline (P<0.05) after the treatment group was treated, and Ht obviously raises (P<0.05), illustrated that treating back patient's blood coagulates, glues, gathers state and all obviously improvement of anemia situation.Two groups relatively, and the low decline of cutting reduced viscosity and erythrocyte sedimentation rate K equation of treatment group all is better than matched group (P<0.05).
In the clinical efficacy process of the test, do not find that medicine of the present invention has obvious adverse reaction.Treatment group part patient has carried out liver function, kidney merit, electrocardiogram detection, all no abnormal change before and after treatment.